Robert Francomano - 14 Mar 2022 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Role
Chief Commercial Officer
Signature
/s/ Robert Francomano
Issuer symbol
SLS
Transactions as of
14 Mar 2022
Net transactions value
$0
Form type
4
Filing time
15 Mar 2022, 16:05:52 UTC
Next filing
03 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLS Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 14 Mar 2022 Common Stock 100,000 $5.23 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-quarter (1/4) of the option shares will vest and became exercisable one year from the March 14, 2022 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter.